Core Viewpoint - 康泰生物 reported a significant increase in revenue and R&D investment, indicating strong growth potential in the vaccine sector and ongoing innovation in vaccine development [1][2] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.392 billion yuan, a year-on-year increase of 15.81% [1] - In Q2, the company generated operating revenue of 747 million yuan, reflecting a quarter-on-quarter growth of 15.76% [1] - R&D investment reached 334 million yuan, up 41.52% year-on-year, accounting for 23.96% of the operating revenue [1] Group 2: Vaccine Development Initiatives - The company is focusing on global innovative vaccine products, particularly developing a vaccine for Klebsiella pneumoniae, which is known for its antibiotic resistance and pathogenicity [1] - 康泰生物 established a joint venture with AstraZeneca to develop innovative vaccines for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with no similar products currently available globally [1] - The company has nearly 30 projects under development, with 3 in the production registration application stage and 15 in clinical trial stages [2] Group 3: Progress on Research Projects - The 60μg recombinant hepatitis B vaccine aimed at preventing recurrence in functional cure populations has received Pre-IND feedback from CDE and is in the process of completing clinical application documentation [2] - The five-in-one vaccine (DTPaHibIPV) has obtained preliminary data from Phase I clinical trials and is currently in discussions with CDE regarding Phase III clinical matters [2] - The 20-valent pneumococcal polysaccharide conjugate vaccine is in Phase I and II clinical trials, while the 24-valent pneumococcal polysaccharide conjugate vaccine has completed preclinical research and received Pre-IND feedback from CDE [2]

Core Viewpoint - Kangtai Biological (300601.SZ) reported a significant decline in net profit for the first half of 2025, despite an increase in revenue, indicating potential challenges in profitability [1] Financial Performance - The company's operating revenue reached 1.392 billion yuan, representing a year-on-year growth of 15.81% [1] - The net profit attributable to shareholders was 37.53 million yuan, a decrease of 77.30% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 18.46 million yuan, down 84.85% year-on-year [1] - Basic earnings per share were reported at 0.03 yuan [1]

（记者 王晓波） 每经AI快讯，康泰生物（SZ 300601，收盘价：18.56元）8月21日晚间发布公告称，2025年半年度，公 司计提信用减值准备、资产减值准备金额共计约1.21亿元，计入公司2025年半年度损益，减少公司2025 年半年度归属于母公司股东的净利润及所有者权益约1.03亿元。本次资产减值对公司持续经营能力不会 产生重大影响。本次计提资产减值准备金额未经审计。 2024年1至12月份，康泰生物的营业收入构成为：生物制品占比98.31%，其他业务收入占比1.69%。 截至发稿，康泰生物市值为207亿元。 每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 ...

Core Insights - 康泰生物 reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The company is focusing on transforming into a global innovative biopharmaceutical enterprise while addressing key public health challenges [2] Financial Performance - The company achieved a net cash flow from operating activities of 75.597 million yuan, an increase of 31.42% year-on-year [1][4] - Cumulative net cash flow from operations for the years 2022 to 2024 is approximately 2.2 billion yuan, indicating a strong financial foundation for sustainable development [4] Research and Development - R&D investment reached 334 million yuan in the first half of 2025, a year-on-year increase of 41.52%, accounting for 23.96% of the revenue [2] - The company has nearly 30 projects in the pipeline, with 3 in the production registration phase and 15 in clinical trials, covering key global vaccine products [3] Product Development - The company is developing a vaccine for Klebsiella pneumoniae, a critical pathogen listed by WHO, targeting high-risk groups [2] - Recent progress includes feedback on a hepatitis B vaccine and initial data from a combined vaccine for pertussis and polio [3] International Expansion - 康泰生物 is expanding its international market presence, focusing on emerging markets along the Belt and Road Initiative, with partnerships in over 20 countries [5] - The company has achieved significant milestones, including GMP certification for its pneumococcal vaccine in Turkey and product registration in Indonesia [5] Future Outlook - The company aims to enhance its commercialization capabilities for existing and future innovative vaccine products through extensive overseas collaborations [6]

Group 1 - The core viewpoint of the article highlights that Kangtai Biological (300601) reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The company's net profit attributable to shareholders decreased to 37.53 million yuan, reflecting a significant decline of 77.3% compared to the previous year [1] - Basic earnings per share for the company stood at 0.03 yuan [1] Group 2 - The company has been actively engaged in the research and development of globally innovative products, including a vaccine for Klebsiella pneumoniae [1]

格隆汇8月21日丨康泰生物(300601.SZ)公布2025年半年度报告，上半年公司实现营业收入13.92亿元，同 比增长15.81%；归属于上市公司股东的净利润3753.27万元，同比下降77.30%；归属于上市公司股东的 扣除非经常性损益的净利润1845.86万元，同比下降84.85%；基本每股收益0.03元。 ...

Core Viewpoint - The company reported a revenue of 1.392 billion yuan for the first half of 2025, reflecting a year-on-year growth of 15.81%. However, the net profit attributable to shareholders decreased significantly by 77.30% to 37.5327 million yuan, with basic earnings per share dropping by 80.00% to 0.03 yuan per share. The company has decided not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1]. Financial Performance - Revenue for the first half of 2025 reached 1.392 billion yuan, marking a 15.81% increase compared to the previous year [1]. - Net profit attributable to shareholders was 37.5327 million yuan, which represents a decline of 77.30% year-on-year [1]. - Basic earnings per share stood at 0.03 yuan, down 80.00% from the same period last year [1]. Dividend Policy - The company announced that it will not distribute cash dividends, issue bonus shares, or utilize reserves for capital increase [1].

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 深圳康泰生物制品股份有限公司 2025 年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳证 券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》及《深圳证券交易所创 业板上市公司自律监管指南第1号——业务办理》等规定，现将深圳康泰生物制品股份有限公 司（以下简称"公司"）2025年半年度募集资金存放、管理与使用情况专项报告如下： 一、募集资金基本情况 二、募集资金存放和管理情况 为规范公司募集资金的存放、管理，保证募集资金的安全，保护投资者的合法利益，根 单位：人民币万元 项目 金额 募集资金净额 198,966.00 减：以前年度已使用金额 191,106.86 减：本报告期使用金额 732.32 加：募集资金利息收入扣减手续费净额 5,4 ...

债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2025-067 深圳康泰生物制品股份有限公司 关于补选战略委员会委员及调整审计委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）于2025年8月21日召 开第八届董事会第六次会议，会议审议通过了《关于补选战略委员会委员及调整 审计委员会委员的议案》，现将相关事项公告如下： 一、补选第八届董事会战略委员会委员的情况 二、调整第八届董事会审计委员会委员的情况 根据《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等法律法规、规范性文件及《公司章程》的相关规定，为进 一步完善公司治理结构，发挥审计委员会的监督作用，公司董事会同意对第八届 董事会审计委员会部分成员进行调整，杜伟民先生不再担任第八届董事会审计委 员会委员职务,其仍担任公司第八届董事会董事、董事长及董事会战略委员会委 员职务，选举职工代表董事李光辉先生为公司第八届董事会审计委员会委员，任 期自本次董事会审议通过 ...

企业负责人： 杜伟民 主管会计工作的负责人： 马建英 会计机构负责人：黄翠冬 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 2025 年期初 占用资金余 | 2025 年 1-6 月占 用累计发生金额 | 2025 年 月偿还累计 | 1-6 | 2025 年半年 度期末占用 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | 占用形成原因 | 占用性质 | | | | 联关系 | 目 | 额 | （不含利息） | 发生金额 | | 资金余额 | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | | | | | ...